The Drugs Controller General (India) has mandated a Digital Monitoring System on the Online National Drugs Licensing System (ONDLS) to track the supply chain—and quality—of high-risk solvents such as Propylene Glycol. The move follows recent fatalities allegedly tied to diethylene glycol (DEG) contamination in cough syrups.
What’s changing (in practice)
-
Single window, single ledger: Solvent makers, importers, distributors, and users will now map licences, batches, and movements to a single federal spine (ONDLS).
-
From licence to lifecycle: Expect periodic submissions beyond licensing—covering procurement → receipt → QC release → dispatch → end-use.
-
Pre-emptive quality gates: DCGI signals equal weight to quality documents (COAs, test results) and movement logs, not just stock flows.
-
Legacy onboarding: Existing manufacturing licences don’t lapse—but you must register and start digital reporting to stay compliant.
Who is covered
-
Manufacturers of pharma-grade solvents (domestic).
-
Importers placing pharma-grade lots into Indian supply chains.
-
Distributors/CFAs/Stockists handling flagged solvent SKUs.
-
Downstream users (formulators) consuming these solvents in drug production.
Likely data ONDLS will expect (workable template)
-
Licence & entity: Manufacturer/importer licence no., validity, site address, approved capacities.
-
Batch & quality: Batch/lot no., mfg/exp dates, COA parameters (identity, purity, water content, aldehydes/DEG/EG limits as applicable), lab details.
-
Movement: Quantity in/out, date-time stamps, GPS-tagged dispatch (optional), transporter, vehicle, e-invoice/waybill refs.
-
Counterparty: Buyer licence no., site address, contact, intended use (formulation/bulk).
-
Exceptions: Deviations, OOS/OOT results, reprocessing/rejections, recalls.
Compliance checklist (10 quick wins)
-
Map SKUs: Identify which solvent grades are classified “high-risk”.
-
Validate licences: Ensure manufacturing/import licences reflect pharma grade scope.
-
Register on ONDLS: Create/verify entity; link all sites and licences.
-
Digitize COAs: Standardize test templates; secure LIMS/e-signatures.
-
Supplier qualification: Re-vet foreign/domestic sources for GMP, pharmacopeial conformance, and impurity controls.
-
Batch traceability: Unique batch IDs, tamper-evident packaging, seal numbers, and reconciled dispatch logs.
-
Goods inward SOPs: Identity testing on every batch; targeted tests for DEG/EG where risk exists.
-
Segregation controls: Physically segregate industrial vs pharma grades; color-coded storage bays and dedicated lines.
-
Deviation handling: NCR/CAPA workflows; 24-hour escalation matrix for OOS results.
-
Mock recalls: Conduct quarterly recall drills; measure time-to-trace to final consignee.
Grey zones to watch
-
Industrial vs pharma grade: Same chemical, different specs. Mixing streams is the core risk—DCGI will expect strong segregation and lab proof.
-
Tolling/third-party processors: Responsibility for data uploads must be contractually clear; assign the “data owner”.
-
Imports via traders: Importer of record carries primary accountability—even if quality testing is outsourced.
How this protects patients (and firms)
-
Earlier risk detection: Structured COA + movement data surfaces anomalies (e.g., unusual impurity trend or odd routes).
-
Faster, narrower recalls: Batch-level maps cut recall scope and financial damage.
-
Better insurance posture: Demonstrable controls support coverage and defend product liability claims.
For State FDAs and CDSCO field units
-
Risk-based inspections: Use ONDLS data to target facilities with frequent deviations or opaque trading chains.
-
Cross-checks: Align ONDLS submissions with e-invoice/waybill patterns to flag ghost movements.
For MSME formulators
-
Minimum viable system: Even Excel + barcode labels + a handheld printer can create a usable trace trail; upgrade to LIMS/ERP over time.
-
Pooling labs: Where in-house GC/LC isn’t feasible, empanel 2–3 accredited labs and fix TAT-SLAs.
Suggested SOP flow (one page)
-
Approve vendor → 2. Procure batch → 3. Quarantine receipt → 4. Sample & test (ID + risk impurities) →5. Release/Reject in LIMS → 6. ONDLS entry (batch, COA, movement) → 7. Issue to production (FIFO/FEFO) → 8. Record consumption → 9. Retain samples & docs (≥5 yrs) → 10. Exception & recall handling.
What could come next
-
Whitelist/blacklist regimes tied to ONDLS conformance.
-
API integration for automated reporting from ERPs/LIMS.
-
Expanded list of high-risk excipients/solvents (e.g., PEGs, glycerin) as surveillance matures.
-
Harmonised COA formats referencing pharmacopeias and impurity thresholds.
Bottom line
The ONDLS directive shifts solvent oversight from paper licences to live, auditable data. If you manufacture, import, or use pharma-grade high-risk solvents, build a clean digital paper trail now—so that safety, recalls, and compliance become routine, not reactive.
Credits: Reporting basis: The Hindu.
